Bendamustine

Generic Name: Bendamustine

Brand Names: Belrapzo, Bendeka, Treanda, Vivimusta

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₂₁Cl_₂N_₃O_₂

CAS Number: 16506-27-7

Unique Ingredient Identifier: 9266D9P3PQ

Background: Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.

Indication: Bendamustine is indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Associated Conditions: Chronic Lymphocytic Leukemia, Follicular Non-Hodgkin's Lymphoma Refractory, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Waldenström's Macroglobulinemia (WM), Recurrent multiple myeloma, Refractory indolent B cell non-hodgkin lymphoma

Associated Therapies: -

Clinical Trials

A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Hodgkin's Lymphoma

Interventions: Drug: Nivolumab
Drug: Bendamustine Hydrochloride

First Posted Date: 2017-11-17

Last Posted Date: 2020-05-28

Lead Sponsor: St. Petersburg State Pavlov Medical University

Target Recruit Count: 30

Registration Number: NCT03343652

Locations: 🇷🇺
First Pavlov State Medical University of St. Petersburg, Saint-Petersburg, Russian Federation

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Phase 3

Active, not recruiting

Conditions: Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions: Drug: Bendamustine
Drug: Zanubrutinib
Drug: Rituximab
Drug: Venetoclax

First Posted Date: 2017-11-08

Last Posted Date: 2023-11-09

Lead Sponsor: BeiGene

Target Recruit Count: 590

Registration Number: NCT03336333

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

and more 175 locations

BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell Transplantation

Phase 2

Conditions: Relapsed/Refractory Malignant Lymphomas

Interventions: Drug: Bendamustine

First Posted Date: 2017-10-20

Last Posted Date: 2018-05-22

Lead Sponsor: State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia

Target Recruit Count: 100

Registration Number: NCT03315520

Locations: 🇷🇺
The Federal Budget-Funded Institution National Medical Surgical Center named after N. I. Pirogov of the Ministry of health of the Russian Federation, Moscow, Russian Federation

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Phase 2

Terminated

Conditions: Mantle Cell Lymphoma
Non-hodgkin Lymphoma
Non Hodgkin Lymphoma

Interventions: Drug: Bendamustine
Drug: Obinutuzumab

First Posted Date: 2017-10-16

Last Posted Date: 2024-10-24

Lead Sponsor: University of Wisconsin, Madison

Target Recruit Count: 21

Registration Number: NCT03311126

Locations: 🇺🇸
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Phase 2

Active, not recruiting

Conditions: Grade 2 Follicular Lymphoma
Grade 3a Follicular Lymphoma
Recurrent Follicular Lymphoma
Grade 1 Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions: Procedure: Biopsy
Drug: Bendamustine Hydrochloride
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Echocardiography
Procedure: Multigated Acquisition Scan
Drug: Lenalidomide
Drug: Cyclophosphamide
Biological: Obinutuzumab
Drug: Doxorubicin Hydrochloride
Procedure: Positron Emission Tomography
Drug: Umbralisib
Drug: Prednisone
Drug: Vincristine Sulfate

First Posted Date: 2017-09-01

Last Posted Date: 2024-11-12

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 95

Registration Number: NCT03269669

Locations: 🇺🇸
Mercy Hospital Saint Louis, Saint Louis, Missouri, United States
🇺🇸
Siteman Cancer Center at Saint Peters Hospital, Saint Peters, Missouri, United States
🇺🇸
Sainte Genevieve County Memorial Hospital, Sainte Genevieve, Missouri, United States

and more 430 locations